Extracellular vesicles from young brain-mediated delivery of PRDX3 ameliorates alveolar bone
By Jiajie Mao, Yuzhu Wu, Yuxian Xia, Jiahui Shen, Xiaoyuan Huang, Shixing Ma, Xiaofeng Yang, Yanhua Lan
Originally at onlinelibrary.wiley.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Research identifies a brain-derived extracellular vesicle pathway that reduces alveolar bone loss in periodontitis, potentially informing future adjunctive therapies for periodontal disease management.
Key points
- YBEVs suppressed inflammatory response in macrophages in vitro and reduced inflammation and bone resorption in vivo.
- Multi-omics analyses including cellular transcriptomics, vesicular cargo transcriptomics, and single-cell profiling of brain tissue implicated PRDX3 as a key effector.
- YBEVs modulate the immune response and NF-κB signalling pathway by delivering PRDX3.
- PRDX3 modulators were employed to explore the NF-κB pathway's impact on inflammatory macrophage in vitro and in vivo.
Who should care
Read the original on Journal of Clinical Periodontology
Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.
Related
- ·Regulatory
In Odessa, an anesthesiologist was charged following the death of a child
- ·Research
Association between local factors and implant-related complications
- ·Research
The osteoimmune cell atlas of peri-implantitis: a narrative scoping review
- ·Research
Ten years and beyond: long-term dental implant survival, success